Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageHalozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Business segments
Jun 2026 · $524.7MThe company’s own SEC segment disclosure.
- Royalty$307.7M59%
- Bulk R Hu PH20$59.6M11%
- Proprietary Products Sales$55.4M11%
- Collaborative Agreements$43.7M8%
- Upfront Fees$35.5M7%
- Device Partnered Products$14.6M3%
- Other (2)$8.2M2%
Halozyme Therapeutics, Inc. (HALO) reported revenue of $377M in Q1 2026 (quarter ended Mar 31, 2026), up 42% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $150M (40% of revenue). For the full year FY2025, revenue was $1.40B (+38% year on year) and net income $317M. Its largest product in Jun 2026 was Royalty at $308M, 59% of the disclosed total, well ahead of Bulk R Hu PH20 at 11%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.